After more than three decades in the pharmaceutical industry, one fundamental truth emerges: science transforms lives, but policy determines whether innovation thrives or stalls. That reality shapes outcomes for patients and defines Europe’s competitive standing in the global economy. Today, Europeans stand at a defining moment where the choices made now will determine whether Europe remains a global leader in life sciences or watches that leadership erode.
The Value of European Life Sciences
It’s essential to recognize the true value of Europe’s life sciences industry and the collective power we possess as a united bloc to protect this European asset. Europe boasts an illustrious track record in medical discovery, from developing the first antibiotics to unlocking the structure of DNA and pioneering today’s advanced biologics therapies.
Our region continues to serve as an engine of medical breakthroughs, powered by an extraordinary ecosystem encompassing innovative start-ups, small and medium-sized enterprises, academic laboratories, and university hospitals. This collaborative strength delivers tangible benefits to patients through access to cutting-edge clinical trials and innovative treatments while establishing life sciences as a strategic pillar of Europe’s economic foundation.
Economic Impact and Strategic Importance
Life sciences represents far more than just another industry sector for Europe—it functions as a growth engine, resilience source, and driver of scientific sovereignty. The European Union already hosts some of the world’s most talented scientists, thriving academic institutions, premier research clusters, and a social model built on universal healthcare access principles. These assets hold tremendous power, yet they only translate into sustained future success when supported by a legislative environment that actively rewards innovation.
The industry currently supports 2.3 million jobs across the continent and contributes over €200 billion annually to the EU economy—surpassing every other sector. EU pharmaceutical research and development spending has demonstrated impressive growth, expanding from €27.8 billion in 2010 to €46.2 billion in 2022, representing an average annual increase of 4.4 percent. While this constitutes a success story, mounting pressures threaten this trajectory.
The Competitive Decline Challenge
Investment Migration Trends
Over the past two decades, Europe has experienced a troubling decline, losing a quarter of its share of global pharmaceutical investment to competing regions. This year marks a historic inflection point—for the first time, China has overtaken both the United States and Europe in the number of newly discovered molecules, signaling a fundamental shift in the innovation landscape.
Clinical Trial Exodus
China has systematically doubled its share of industry-sponsored clinical trials, while Europe’s proportion has been cut in half. This decline translates to 60,000 European patients losing opportunities to participate in trials testing next-generation treatments. The implications extend beyond statistics—every clinical trial site relocated elsewhere means European patients wait longer for access to breakthrough therapies, and the entire ecosystem gradually loses its competitive edge.
Global Policy Shifts Reshaping Markets
While Europe engages in prolonged debates, competitor nations are taking decisive action. The United States and Asian markets are streamlining regulatory frameworks, accelerating drug approval processes, and attracting pharmaceutical capital at unprecedented scales. Policy environments determine whether innovation can establish roots and flourish.
The American Policy Revolution
Global dynamics are shifting in unprecedented ways. The United States administration’s renewed push for a Most Favored Nation drug pricing policy—designed to link domestic prices to the lowest rates paid in developed markets—combined with potential removal of longstanding tariff exemptions for medicines exported from Europe, represents a historic turning point.
A fundamental reordering of the global pharmaceutical landscape is underway. The message resonates clearly: innovation competitiveness has become a geopolitical priority. Europe must recognize and respond to this reality with equal urgency.
A Framework for Future Success
The Critical Legislative Moment
The timing presents a unique opportunity. Europe is currently rewriting pharmaceutical legislation that will define the next two decades of innovation policy. This represents a once-in-a-generation reset, but only if reforms strengthen rather than undermine Europe’s ability to compete effectively in life sciences.
The Triple-A Strategic Framework
To lead globally, Europe must make decisive choices through a comprehensive approach encompassing three core priorities:
Attract global investment by ensuring robust intellectual property protection, predictable regulatory frameworks, and competitive incentives—the foundational elements of a world-class innovation ecosystem that draws research and development capital.
Accelerate the pathway from scientific discovery to patient care. Europe’s regulatory system must match the pace of scientific progress, ensuring breakthrough therapies reach patients more rapidly without compromising safety standards.
Access must be equitable and timely for all European patients. No innovation should remain inaccessible due to administrative delays or fragmented decision-making across 27 member state systems.
These priorities create synergistic effects, generating a virtuous cycle that simultaneously strengthens competitiveness, improves health outcomes, and drives sustainable economic growth.
Industry Investment Reality
Despite flat or declining public investment in new medicines across most member states over the past 20 years, the research-based pharmaceutical industry has significantly increased its contributions. Industry contributions to public pharmaceutical expenditure doubled from 12 percent to 24 percent between 2018 and 2023. Effectively, the sector has financed its own innovation at a scale unmatched by any other industry. However, this model cannot continue indefinitely. Pharmaceutical innovation must be recognized not as a cost to contain, but as a strategic investment in Europe’s future prosperity and health security.
The Path Forward
Europe’s Unique Advantages
Europe possesses everything required to shape the future of medicine: world-class scientific infrastructure, exceptional talent pools, a 500-million-strong unified market, and one of the most sophisticated pharmaceutical manufacturing bases globally. What’s needed now is political ambition equal to these remarkable assets.
The Decisive Choice
If we choose to prioritize innovation, we secure Europe’s high-quality jobs, research leadership, and global competitiveness—ensuring European patients benefit first from next-generation medical breakthroughs. Conversely, a wrong decision will reverberate negatively for decades, diminishing Europe’s position in one of the 21st century’s most critical industries.
The next chapter of European pharmaceutical leadership is being written now. Let us choose the path that keeps Europe leading, competing, and innovating—for our economies, our societies, and above all, our patients. Choose Europe. Choose innovation. Choose a future where scientific excellence and policy wisdom converge to deliver health security and economic prosperity for generations to come.
